Table of Contents

Chapter 1 Overview of Oncology Biomarker

• 1.1 Definition of Oncology Biomarker in This Report
• 1.2 Commercial Types of Oncology Biomarker
  • 1.2.1 Lung Cancer
  • 1.2.2 Breast Cancer
  • 1.2.3 Colorectal Cancer
  • 1.2.4 Prostate Cancer
  • 1.2.5 Stomach Cancer
  • 1.2.6 Others
• 1.3 Downstream Application of Oncology Biomarker
  • 1.3.1 Diagnostics
  • 1.3.2 Drug Discovery And Development
  • 1.3.3 Prognostics
  • 1.3.4 Risk Assessment
  • 1.3.5 Others
• 1.4 Development History of Oncology Biomarker
• 1.5 Market Status and Trend of Oncology Biomarker 2013-2023
  • 1.5.1 Global Oncology Biomarker Market Status and Trend 2013-2023
  • 1.5.2 Regional Oncology Biomarker Market Status and Trend 2013-2023

Chapter 2 Global Market Status and Forecast by Regions

• 2.1 Market Development of Oncology Biomarker 2013-2017
• 2.2 Production Market of Oncology Biomarker by Regions
  • 2.2.1 Production Volume of Oncology Biomarker by Regions
  • 2.2.2 Production Value of Oncology Biomarker by Regions
• 2.3 Demand Market of Oncology Biomarker by Regions
• 2.4 Production and Demand Status of Oncology Biomarker by Regions
  • 2.4.1 Production and Demand Status of Oncology Biomarker by Regions 2013-2017
  • 2.4.2 Import and Export Status of Oncology Biomarker by Regions 2013-2017

Chapter 3 Global Market Status and Forecast by Types

• 3.1 Production Volume of Oncology Biomarker by Types
• 3.2 Production Value of Oncology Biomarker by Types
• 3.3 Market Forecast of Oncology Biomarker by Types

Chapter 4 Global Market Status and Forecast by Downstream Industry

• 4.1 Demand Volume of Oncology Biomarker by Downstream Industry
• 4.2 Market Forecast of Oncology Biomarker by Downstream Industry

Chapter 5 Market Driving Factor Analysis of Oncology Biomarker

• 5.1 Global Economy Situation and Trend Overview
• 5.2 Oncology Biomarker Downstream Industry Situation and Trend Overview

Chapter 6 Oncology Biomarker Market Competition Status by Major Manufacturers

• 6.1 Production Volume of Oncology Biomarker by Major Manufacturers
• 6.2 Production Value of Oncology Biomarker by Major Manufacturers
• 6.3 Basic Information of Oncology Biomarker by Major Manufacturers
  • 6.3.1 Headquarters Location and Established Time of Oncology Biomarker Major Manufacturer
  • 6.3.2 Employees and Revenue Level of Oncology Biomarker Major Manufacturer
• 6.4 Market Competition News and Trend
  • 6.4.1 Merger, Consolidation or Acquisition News
  • 6.4.2 Investment or Disinvestment News
  • 6.4.3 New Product Development and Launch

Chapter 7 Oncology Biomarker Major Manufacturers Introduction and Market Data

• 7.1 Novartis AG
  • 7.1.1 Company profile
  • 7.1.2 Representative Oncology Biomarker Product
  • 7.1.3 Oncology Biomarker Sales, Revenue, Price and Gross Margin of Novartis AG
• 7.2 Merck & Co.
  • 7.2.1 Company profile
  • 7.2.2 Representative Oncology Biomarker Product
  • 7.2.3 Oncology Biomarker Sales, Revenue, Price and Gross Margin of Merck & Co.
• 7.3 F.Hoffmann-La Roche Ltd.
  • 7.3.1 Company profile
  • 7.3.2 Representative Oncology Biomarker Product
  • 7.3.3 Oncology Biomarker Sales, Revenue, Price and Gross Margin of F.Hoffmann-La Roche Ltd.
• 7.4 Bristol-Myers Squibb
  • 7.4.1 Company profile
  • 7.4.2 Representative Oncology Biomarker Product
  • 7.4.3 Oncology Biomarker Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb
• 7.5 Abbott Laboratories
  • 7.5.1 Company profile
  • 7.5.2 Representative Oncology Biomarker Product
  • 7.5.3 Oncology Biomarker Sales, Revenue, Price and Gross Margin of Abbott Laboratories
• 7.6 Eli Lilly and Company
  • 7.6.1 Company profile
  • 7.6.2 Representative Oncology Biomarker Product
  • 7.6.3 Oncology Biomarker Sales, Revenue, Price and Gross Margin of Eli Lilly and Company
• 7.7 Qiagen N.V.
  • 7.7.1 Company profile
  • 7.7.2 Representative Oncology Biomarker Product
  • 7.7.3 Oncology Biomarker Sales, Revenue, Price and Gross Margin of Qiagen N.V.
• 7.8 GlaxoSmithKline plc
  • 7.8.1 Company profile
  • 7.8.2 Representative Oncology Biomarker Product
  • 7.8.3 Oncology Biomarker Sales, Revenue, Price and Gross Margin of GlaxoSmithKline plc
• 7.9 Genomic Health
  • 7.9.1 Company profile
  • 7.9.2 Representative Oncology Biomarker Product
  • 7.9.3 Oncology Biomarker Sales, Revenue, Price and Gross Margin of Genomic Health
• 7.10 Pfizer
  • 7.10.1 Company profile
  • 7.10.2 Representative Oncology Biomarker Product
  • 7.10.3 Oncology Biomarker Sales, Revenue, Price and Gross Margin of Pfizer

Chapter 8 Upstream and Downstream Market Analysis of Oncology Biomarker

• 8.1 Industry Chain of Oncology Biomarker
• 8.2 Upstream Market and Representative Companies Analysis
• 8.3 Downstream Market and Representative Companies Analysis

Chapter 9 Cost and Gross Margin Analysis of Oncology Biomarker

• 9.1 Cost Structure Analysis of Oncology Biomarker
• 9.2 Raw Materials Cost Analysis of Oncology Biomarker
• 9.3 Labor Cost Analysis of Oncology Biomarker
• 9.4 Manufacturing Expenses Analysis of Oncology Biomarker

Chapter 10 Marketing Status Analysis of Oncology Biomarker

• 10.1 Marketing Channel
  • 10.1.1 Direct Marketing
  • 10.1.2 Indirect Marketing
  • 10.1.3 Marketing Channel Development Trend
• 10.2 Market Positioning
  • 10.2.1 Pricing Strategy
  • 10.2.2 Brand Strategy
  • 10.2.3 Target Client
• 10.3 Distributors/Traders List

Chapter 11 Report Conclusion

Chapter 12 Research Methodology and Reference

• 12.1 Methodology/Research Approach
  • 12.1.1 Research Programs/Design
  • 12.1.2 Market Size Estimation
  • 12.1.3 Market Breakdown and Data Triangulation
• 12.2 Data Source
  • 12.2.1 Secondary Sources
  • 12.2.2 Primary Sources

Report Summary

Oncology Biomarker -Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Oncology Biomarker industry, standing on the readers’ perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Oncology Biomarker 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Oncology Biomarker worldwide, with company and product introduction, position in the Oncology Biomarker market
Market status and development trend of Oncology Biomarker by types and applications
Cost and profit status of Oncology Biomarker , and marketing status
Market growth drivers and challenges

The report segments the global Oncology Biomarker market as:

Global Oncology Biomarker Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America
Europe
China
Japan
Rest APAC
Latin America

Global Oncology Biomarker Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Stomach Cancer
Others

Global Oncology Biomarker Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Diagnostics
Drug Discovery And Development
Prognostics
Risk Assessment
Others

Global Oncology Biomarker Market: Manufacturers Segment Analysis (Company and Product introduction, Oncology Biomarker Sales Volume, Revenue, Price and Gross Margin):
Novartis AG
Merck & Co.
F.Hoffmann-La Roche Ltd.
Bristol-Myers Squibb
Abbott Laboratories
Eli Lilly and Company
Qiagen N.V.
GlaxoSmithKline plc
Genomic Health
Pfizer

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.